• Home
  • 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.

Author List
Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT
Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication ID (Profile URL)
https://researcherprofiles.org/profile/559125586
Publication Year
2024
PubMed ID
39471458
Publication Title
Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29.